Does the media prefer NEUP or BRTX?

In the previous week, Neuphoria Therapeutics had 1 more articles in the media than Biorestorative Therapies. MarketBeat recorded 4 mentions for Neuphoria Therapeutics and 3 mentions for Biorestorative Therapies. Biorestorative Therapies' average media sentiment score of 0.96 beat Neuphoria Therapeutics' score of 0.29 indicating that Biorestorative Therapies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuphoria Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biorestorative Therapies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend NXTC or BRTX?

NextCure currently has a consensus target price of $19.00, suggesting a potential upside of 131.43%. Given NextCure's stronger consensus rating and higher probable upside, research analysts clearly believe NextCure is more favorable than Biorestorative Therapies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NextCure 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to NXTC or BRTX?

In the previous week, NextCure had 6 more articles in the media than Biorestorative Therapies. MarketBeat recorded 9 mentions for NextCure and 3 mentions for Biorestorative Therapies. NextCure's average media sentiment score of 0.96 equaled Biorestorative Therapies'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NextCure 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biorestorative Therapies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ALLR or BRTX?

In the previous week, Allarity Therapeutics had 2 more articles in the media than Biorestorative Therapies. MarketBeat recorded 5 mentions for Allarity Therapeutics and 3 mentions for Biorestorative Therapies. Biorestorative Therapies' average media sentiment score of 0.96 beat Allarity Therapeutics' score of 0.62 indicating that Biorestorative Therapies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allarity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biorestorative Therapies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer BRTX or MRKR?

Marker Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 777.19%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Marker Therapeutics is more favorable than Biorestorative Therapies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Marker Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts recommend CELU or BRTX?

Celularity presently has a consensus price target of $6.00, indicating a potential upside of 762.32%. Given Celularity's stronger consensus rating and higher possible upside, research analysts clearly believe Celularity is more favorable than Biorestorative Therapies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celularity 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Biorestorative Therapies (BRTX) Competitors

$0.23 +0.01 (+2.59%)

Closing price 04:00 PM Eastern

Extended Trading

$0.22 0.00 (-1.28%)

As of 07:32 PM Eastern

Compare

BRTX vs. NEUP, NXTC, ALLR, MRKR, and CELU

Should you buy Biorestorative Therapies stock or one of its competitors? Biorestorative Therapies's main competitors and comparable companies include Neuphoria Therapeutics (NEUP), NextCure (NXTC), Allarity Therapeutics (ALLR), Marker Therapeutics (MRKR), and Celularity (CELU). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Biorestorative Therapies compare to Neuphoria Therapeutics?

Neuphoria Therapeutics (NASDAQ:NEUP) and Biorestorative Therapies (NASDAQ:BRTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Neuphoria Therapeutics has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market. Comparatively, Biorestorative Therapies has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

In the previous week, Neuphoria Therapeutics had 1 more articles in the media than Biorestorative Therapies. MarketBeat recorded 4 mentions for Neuphoria Therapeutics and 3 mentions for Biorestorative Therapies. Biorestorative Therapies' average media sentiment score of 0.96 beat Neuphoria Therapeutics' score of 0.29 indicating that Biorestorative Therapies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuphoria Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biorestorative Therapies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.9% of Neuphoria Therapeutics shares are held by institutional investors. Comparatively, 69.4% of Biorestorative Therapies shares are held by institutional investors. 1.5% of Neuphoria Therapeutics shares are held by company insiders. Comparatively, 13.6% of Biorestorative Therapies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Neuphoria Therapeutics has a net margin of 0.00% compared to Biorestorative Therapies' net margin of -3,088.27%. Neuphoria Therapeutics' return on equity of -76.93% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-76.93%	-54.76%
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%

Neuphoria Therapeutics currently has a consensus price target of $21.00, indicating a potential upside of 442.64%. Given Neuphoria Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Neuphoria Therapeutics is more favorable than Biorestorative Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Neuphoria Therapeutics has higher revenue and earnings than Biorestorative Therapies. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$15.65M	1.34	-$370K	-$11.06	N/A
Biorestorative Therapies	$360K	15.99	-$14.24M	-$1.07	N/A

Summary

Neuphoria Therapeutics beats Biorestorative Therapies on 9 of the 16 factors compared between the two stocks.

How does Biorestorative Therapies compare to NextCure?

NextCure (NASDAQ:NXTC) and Biorestorative Therapies (NASDAQ:BRTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

42.7% of NextCure shares are owned by institutional investors. Comparatively, 69.4% of Biorestorative Therapies shares are owned by institutional investors. 11.9% of NextCure shares are owned by insiders. Comparatively, 13.6% of Biorestorative Therapies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, NextCure had 6 more articles in the media than Biorestorative Therapies. MarketBeat recorded 9 mentions for NextCure and 3 mentions for Biorestorative Therapies. NextCure's average media sentiment score of 0.96 equaled Biorestorative Therapies'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NextCure	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biorestorative Therapies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biorestorative Therapies has higher revenue and earnings than NextCure. NextCure is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A
Biorestorative Therapies	$360K	15.99	-$14.24M	-$1.07	N/A

NextCure currently has a consensus target price of $19.00, suggesting a potential upside of 131.43%. Given NextCure's stronger consensus rating and higher probable upside, research analysts clearly believe NextCure is more favorable than Biorestorative Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NextCure has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Comparatively, Biorestorative Therapies has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

NextCure has a net margin of 0.00% compared to Biorestorative Therapies' net margin of -3,088.27%. NextCure's return on equity of -154.62% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NextCure	N/A	-154.62%	-100.19%
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%

Summary

NextCure beats Biorestorative Therapies on 8 of the 14 factors compared between the two stocks.

How does Biorestorative Therapies compare to Allarity Therapeutics?

Allarity Therapeutics (NASDAQ:ALLR) and Biorestorative Therapies (NASDAQ:BRTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Allarity Therapeutics has higher earnings, but lower revenue than Biorestorative Therapies. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$320K	68.11	-$11.23M	-$0.72	N/A
Biorestorative Therapies	$360K	15.99	-$14.24M	-$1.07	N/A

11.5% of Allarity Therapeutics shares are held by institutional investors. Comparatively, 69.4% of Biorestorative Therapies shares are held by institutional investors. 0.2% of Allarity Therapeutics shares are held by insiders. Comparatively, 13.6% of Biorestorative Therapies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Allarity Therapeutics has a net margin of 0.00% compared to Biorestorative Therapies' net margin of -3,088.27%. Allarity Therapeutics' return on equity of -109.94% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-109.94%	-47.27%
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%

Allarity Therapeutics presently has a consensus target price of $10.25, indicating a potential upside of 648.18%. Given Allarity Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Allarity Therapeutics is more favorable than Biorestorative Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Allarity Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, Biorestorative Therapies has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market.

In the previous week, Allarity Therapeutics had 2 more articles in the media than Biorestorative Therapies. MarketBeat recorded 5 mentions for Allarity Therapeutics and 3 mentions for Biorestorative Therapies. Biorestorative Therapies' average media sentiment score of 0.96 beat Allarity Therapeutics' score of 0.62 indicating that Biorestorative Therapies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allarity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biorestorative Therapies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Allarity Therapeutics beats Biorestorative Therapies on 10 of the 16 factors compared between the two stocks.

How does Biorestorative Therapies compare to Marker Therapeutics?

Biorestorative Therapies (NASDAQ:BRTX) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Marker Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 777.19%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Marker Therapeutics is more favorable than Biorestorative Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Biorestorative Therapies had 1 more articles in the media than Marker Therapeutics. MarketBeat recorded 3 mentions for Biorestorative Therapies and 2 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 1.87 beat Biorestorative Therapies' score of 0.96 indicating that Marker Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Biorestorative Therapies	Positive
Marker Therapeutics	Very Positive

Biorestorative Therapies has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market.

69.4% of Biorestorative Therapies shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 13.6% of Biorestorative Therapies shares are held by company insiders. Comparatively, 5.7% of Marker Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Marker Therapeutics has higher revenue and earnings than Biorestorative Therapies. Marker Therapeutics is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biorestorative Therapies	$360K	15.99	-$14.24M	-$1.07	N/A
Marker Therapeutics	$3.55M	5.35	-$12.16M	-$0.61	N/A

Marker Therapeutics has a net margin of -343.03% compared to Biorestorative Therapies' net margin of -3,088.27%. Marker Therapeutics' return on equity of -73.29% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%
Marker Therapeutics	-343.03%	-73.29%	-59.70%

Summary

Marker Therapeutics beats Biorestorative Therapies on 11 of the 16 factors compared between the two stocks.

How does Biorestorative Therapies compare to Celularity?

Celularity (NASDAQ:CELU) and Biorestorative Therapies (NASDAQ:BRTX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Celularity presently has a consensus price target of $6.00, indicating a potential upside of 762.32%. Given Celularity's stronger consensus rating and higher possible upside, research analysts clearly believe Celularity is more favorable than Biorestorative Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

19.0% of Celularity shares are held by institutional investors. Comparatively, 69.4% of Biorestorative Therapies shares are held by institutional investors. 17.3% of Celularity shares are held by insiders. Comparatively, 13.6% of Biorestorative Therapies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Celularity has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market. Comparatively, Biorestorative Therapies has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market.

In the previous week, Biorestorative Therapies had 2 more articles in the media than Celularity. MarketBeat recorded 3 mentions for Biorestorative Therapies and 1 mentions for Celularity. Celularity's average media sentiment score of 1.89 beat Biorestorative Therapies' score of 0.96 indicating that Celularity is being referred to more favorably in the media.

Company	Overall Sentiment
Celularity	Very Positive
Biorestorative Therapies	Positive

Biorestorative Therapies has lower revenue, but higher earnings than Celularity. Biorestorative Therapies is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	0.76	-$91.72M	-$3.33	N/A
Biorestorative Therapies	$360K	15.99	-$14.24M	-$1.07	N/A

Celularity has a net margin of -345.45% compared to Biorestorative Therapies' net margin of -3,088.27%. Celularity's return on equity of 0.00% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%

Summary

Celularity beats Biorestorative Therapies on 10 of the 16 factors compared between the two stocks.

Get Biorestorative Therapies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BRTX vs. The Competition

Export

Metric	Biorestorative Therapies	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.61M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-0.21	10.67	269.06	25.28
Price / Sales	15.99	1,262.99	592.57	87.62
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	5.65	16.78	12.91	6.24
Net Income	-$14.24M	-$13.32M	$3.45B	$347.60M
7 Day Performance	10.74%	1.74%	1.12%	1.07%
1 Month Performance	-31.55%	1.60%	1.79%	1.03%
1 Year Performance	-84.94%	56.43%	67.69%	20.77%

Biorestorative Therapies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BRTX Biorestorative Therapies	1.5316 of 5 stars	$0.23 +2.6%	N/A	-85.3%	$5.61M	$360K	N/A	7	Short Interest Decrease Gap Up
NEUP Neuphoria Therapeutics	2.3739 of 5 stars	$3.95 +1.5%	$21.00 +431.6%	-51.8%	$21.02M	$15.65M	N/A	N/A	Short Interest Increase
NXTC NextCure	4.5119 of 5 stars	$5.25 -9.2%	$19.00 +261.9%	+59.5%	$20.88M	N/A	N/A	90	Analyst Upgrade Short Interest Decrease Analyst Revision
ALLR Allarity Therapeutics	2.4316 of 5 stars	$1.33 +1.5%	$10.25 +670.7%	+36.0%	$20.84M	$320K	N/A	10	News Coverage Earnings Report Upcoming Earnings Gap Up
MRKR Marker Therapeutics	2.7897 of 5 stars	$1.15 -6.9%	$10.00 +773.4%	-14.0%	$20.51M	$3.55M	N/A	60	Positive News Earnings Report Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BRTX) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biorestorative Therapies (BRTX) Competitors

BRTX vs. NEUP, NXTC, ALLR, MRKR, and CELU

How does Biorestorative Therapies compare to Neuphoria Therapeutics?

Summary

How does Biorestorative Therapies compare to NextCure?

Summary

How does Biorestorative Therapies compare to Allarity Therapeutics?

Summary

How does Biorestorative Therapies compare to Marker Therapeutics?

Summary

How does Biorestorative Therapies compare to Celularity?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRTX vs. The Competition

Biorestorative Therapies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biorestorative Therapies (BRTX) Competitors

BRTX vs. NEUP, NXTC, ALLR, MRKR, and CELU

How does Biorestorative Therapies compare to Neuphoria Therapeutics?

Which has more volatility and risk, NEUP or BRTX?

Does the media prefer NEUP or BRTX?

Do insiders & institutionals believe in NEUP or BRTX?

Is NEUP or BRTX more profitable?

Do analysts prefer NEUP or BRTX?

Which has higher earnings and valuation, NEUP or BRTX?

Summary

How does Biorestorative Therapies compare to NextCure?

Do insiders & institutionals have more ownership in NXTC or BRTX?

Does the media refer more to NXTC or BRTX?

Which has better earnings and valuation, NXTC or BRTX?

Do analysts recommend NXTC or BRTX?

Which has more volatility and risk, NXTC or BRTX?

Is NXTC or BRTX more profitable?

Summary

How does Biorestorative Therapies compare to Allarity Therapeutics?

Which has better earnings & valuation, ALLR or BRTX?

Do institutionals and insiders hold more shares of ALLR or BRTX?

Is ALLR or BRTX more profitable?

Do analysts prefer ALLR or BRTX?

Which has more risk & volatility, ALLR or BRTX?

Does the media prefer ALLR or BRTX?

Summary

How does Biorestorative Therapies compare to Marker Therapeutics?

Do analysts prefer BRTX or MRKR?

Does the media prefer BRTX or MRKR?

Which has more risk & volatility, BRTX or MRKR?

Do institutionals and insiders have more ownership in BRTX or MRKR?

Which has preferable valuation & earnings, BRTX or MRKR?

Is BRTX or MRKR more profitable?

Summary

How does Biorestorative Therapies compare to Celularity?

Do analysts recommend CELU or BRTX?

Do institutionals and insiders believe in CELU or BRTX?

Which has more volatility & risk, CELU or BRTX?

Does the media refer more to CELU or BRTX?

Which has preferable earnings & valuation, CELU or BRTX?

Is CELU or BRTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRTX vs. The Competition

Biorestorative Therapies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools